BRPI0007714B8 - processo para preparação de liofilizados da substância metanossulfanato de 2-metil-5-metilsulfonil-4-(1-pirrolil) benzoilguanidina que apresentam uma taxa de dissolução melhorada, e preparação farcêutica compreendendo os mesmos. - Google Patents
processo para preparação de liofilizados da substância metanossulfanato de 2-metil-5-metilsulfonil-4-(1-pirrolil) benzoilguanidina que apresentam uma taxa de dissolução melhorada, e preparação farcêutica compreendendo os mesmos.Info
- Publication number
- BRPI0007714B8 BRPI0007714B8 BRPI0007714A BR0007714A BRPI0007714B8 BR PI0007714 B8 BRPI0007714 B8 BR PI0007714B8 BR PI0007714 A BRPI0007714 A BR PI0007714A BR 0007714 A BR0007714 A BR 0007714A BR PI0007714 B8 BRPI0007714 B8 BR PI0007714B8
- Authority
- BR
- Brazil
- Prior art keywords
- lyophilisates
- dissolution rate
- methanesulfate
- benzoylguanidine
- methylsulfonyl
- Prior art date
Links
- 238000004090 dissolution Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- UADMBZFZZOBWBB-UHFFFAOYSA-N n-(diaminomethylidene)-2-methyl-5-methylsulfonyl-4-pyrrol-1-ylbenzamide Chemical compound C1=C(C(=O)N=C(N)N)C(C)=CC(N2C=CC=C2)=C1S(C)(=O)=O UADMBZFZZOBWBB-UHFFFAOYSA-N 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 238000003303 reheating Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mechanical Engineering (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Waveguide Aerials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19903275.0 | 1999-01-28 | ||
| DE19903275A DE19903275A1 (de) | 1999-01-28 | 1999-01-28 | Lyophilisate mit verbesserter Rekonstituierbarkeit |
| PCT/EP2000/000569 WO2000044354A1 (de) | 1999-01-28 | 2000-01-26 | Lyophilisate mit verbesserter rekonstituierbarkeit |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0007714A BR0007714A (pt) | 2001-11-27 |
| BR0007714B1 BR0007714B1 (pt) | 2014-09-30 |
| BRPI0007714B8 true BRPI0007714B8 (pt) | 2021-05-25 |
Family
ID=7895601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0007714A BRPI0007714B8 (pt) | 1999-01-28 | 2000-01-26 | processo para preparação de liofilizados da substância metanossulfanato de 2-metil-5-metilsulfonil-4-(1-pirrolil) benzoilguanidina que apresentam uma taxa de dissolução melhorada, e preparação farcêutica compreendendo os mesmos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6770678B1 (https=) |
| EP (1) | EP1146863B1 (https=) |
| JP (2) | JP4562288B2 (https=) |
| KR (1) | KR20010108136A (https=) |
| AT (1) | ATE266387T1 (https=) |
| AU (1) | AU757781B2 (https=) |
| BR (1) | BRPI0007714B8 (https=) |
| CA (1) | CA2361237C (https=) |
| CZ (1) | CZ20012693A3 (https=) |
| DE (2) | DE19903275A1 (https=) |
| DK (1) | DK1146863T3 (https=) |
| ES (1) | ES2220404T3 (https=) |
| HU (1) | HU226585B1 (https=) |
| NO (1) | NO331321B1 (https=) |
| PL (1) | PL351140A1 (https=) |
| PT (1) | PT1146863E (https=) |
| RU (1) | RU2225709C2 (https=) |
| SK (1) | SK10542001A3 (https=) |
| UA (1) | UA70351C2 (https=) |
| WO (1) | WO2000044354A1 (https=) |
| ZA (1) | ZA200107081B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1469827B1 (en) * | 2002-01-09 | 2017-12-27 | Emisphere Technologies, Inc. | Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
| DE102004045825A1 (de) * | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Lyophilisat enthaltend N-Diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| RU2299063C1 (ru) * | 2006-03-03 | 2007-05-20 | Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора) | Способ сушки термолабильного биологически активного препарата |
| DK2271327T3 (en) | 2008-05-09 | 2015-07-13 | Merck Patent Gmbh | Pharmaceutical composition comprising rhymeporide for the treatment of diseases associated with beta-cell dysfunction |
| US8183267B2 (en) * | 2008-06-09 | 2012-05-22 | Awd. Pharma Gmbh & Co. Kg | Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine |
| US7795263B2 (en) * | 2008-07-08 | 2010-09-14 | Wildlife Laboratories, Inc. | Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals |
| US10584123B2 (en) * | 2017-09-27 | 2020-03-10 | Fedora Pharmaceuticals Inc. | Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof |
| WO2019131223A1 (ja) * | 2017-12-28 | 2019-07-04 | 富士フイルム富山化学株式会社 | 凍結乾燥製剤の製造方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002748A (en) | 1976-01-19 | 1977-01-11 | Eli Lilly And Company | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration |
| JPH07114946B2 (ja) * | 1988-10-24 | 1995-12-13 | 株式会社奈良機械製作所 | 難溶性物質の処理方法 |
| US5066647A (en) * | 1989-04-20 | 1991-11-19 | Erbamont, Inc. | Cyclophosphamide - alanine lyophilizates |
| EP0589336B1 (de) * | 1992-09-22 | 1997-01-08 | Hoechst Aktiengesellschaft | Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika |
| JP2747967B2 (ja) * | 1993-07-23 | 1998-05-06 | 雪印乳業株式会社 | シアル酸粉末 |
| ZA949182B (en) * | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
| DE4430861A1 (de) * | 1994-08-31 | 1996-03-07 | Merck Patent Gmbh | Heterocyclyl-benzoylguanidine |
| RU2105569C1 (ru) * | 1995-06-05 | 1998-02-27 | Индивидуальное частное предприятие Фирма "Брынцалов" | Способ получения лекарственной формы противоопухолевого антибиотика |
| DE19529612A1 (de) * | 1995-08-11 | 1997-02-13 | Merck Patent Gmbh | Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate |
| RU2111426C1 (ru) * | 1995-11-03 | 1998-05-20 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Способ лиофильной сушки биопрепарата |
| JPH09183729A (ja) * | 1995-12-29 | 1997-07-15 | Meiji Milk Prod Co Ltd | 凍結乾燥ウラシルを含有する抗腫瘍医薬組成物 |
-
1999
- 1999-01-28 DE DE19903275A patent/DE19903275A1/de not_active Withdrawn
-
2000
- 2000-01-26 JP JP2000595658A patent/JP4562288B2/ja not_active Expired - Lifetime
- 2000-01-26 SK SK1054-2001A patent/SK10542001A3/sk unknown
- 2000-01-26 ES ES00906226T patent/ES2220404T3/es not_active Expired - Lifetime
- 2000-01-26 CZ CZ20012693A patent/CZ20012693A3/cs unknown
- 2000-01-26 UA UA2001085974A patent/UA70351C2/uk unknown
- 2000-01-26 BR BRPI0007714A patent/BRPI0007714B8/pt not_active IP Right Cessation
- 2000-01-26 AU AU27986/00A patent/AU757781B2/en not_active Expired
- 2000-01-26 CA CA002361237A patent/CA2361237C/en not_active Expired - Lifetime
- 2000-01-26 DE DE50006404T patent/DE50006404D1/de not_active Expired - Lifetime
- 2000-01-26 EP EP00906226A patent/EP1146863B1/de not_active Expired - Lifetime
- 2000-01-26 US US09/889,930 patent/US6770678B1/en not_active Expired - Lifetime
- 2000-01-26 HU HU0105493A patent/HU226585B1/hu not_active IP Right Cessation
- 2000-01-26 AT AT00906226T patent/ATE266387T1/de active
- 2000-01-26 PL PL00351140A patent/PL351140A1/xx unknown
- 2000-01-26 RU RU2001122707/15A patent/RU2225709C2/ru active
- 2000-01-26 KR KR1020017009423A patent/KR20010108136A/ko not_active Ceased
- 2000-01-26 WO PCT/EP2000/000569 patent/WO2000044354A1/de not_active Ceased
- 2000-01-26 PT PT00906226T patent/PT1146863E/pt unknown
- 2000-01-26 DK DK00906226T patent/DK1146863T3/da active
-
2001
- 2001-07-27 NO NO20013703A patent/NO331321B1/no not_active IP Right Cessation
- 2001-08-27 ZA ZA200107081A patent/ZA200107081B/xx unknown
-
2010
- 2010-06-02 JP JP2010126408A patent/JP2010264249A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HU226585B1 (en) | 2009-04-28 |
| BR0007714A (pt) | 2001-11-27 |
| HUP0105493A3 (en) | 2006-07-28 |
| ATE266387T1 (de) | 2004-05-15 |
| SK10542001A3 (sk) | 2002-01-07 |
| JP2010264249A (ja) | 2010-11-25 |
| BR0007714B1 (pt) | 2014-09-30 |
| EP1146863B1 (de) | 2004-05-12 |
| JP4562288B2 (ja) | 2010-10-13 |
| HUP0105493A2 (en) | 2002-06-29 |
| AU757781B2 (en) | 2003-03-06 |
| NO331321B1 (no) | 2011-11-21 |
| NO20013703L (no) | 2001-07-27 |
| PT1146863E (pt) | 2004-10-29 |
| EP1146863A1 (de) | 2001-10-24 |
| ZA200107081B (en) | 2003-02-26 |
| DK1146863T3 (da) | 2004-08-30 |
| CZ20012693A3 (cs) | 2002-01-16 |
| DE19903275A1 (de) | 2000-08-03 |
| ES2220404T3 (es) | 2004-12-16 |
| CA2361237C (en) | 2008-07-15 |
| KR20010108136A (ko) | 2001-12-07 |
| DE50006404D1 (de) | 2004-06-17 |
| US6770678B1 (en) | 2004-08-03 |
| RU2225709C2 (ru) | 2004-03-20 |
| PL351140A1 (en) | 2003-03-24 |
| AU2798600A (en) | 2000-08-18 |
| UA70351C2 (en) | 2004-10-15 |
| NO20013703D0 (no) | 2001-07-27 |
| CA2361237A1 (en) | 2000-08-03 |
| WO2000044354A1 (de) | 2000-08-03 |
| JP2002535089A (ja) | 2002-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0314071A (pt) | Derivados de pró-droga de 1,3-diamino-2-hidroxipropano | |
| BR9916732A (pt) | Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa) | |
| BR0316407A (pt) | Derivados de nucleosìdeo antiviral | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| CA2288445A1 (en) | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives | |
| BR9905788A (pt) | Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados | |
| BR112013027028A2 (pt) | preparo de gadobutrol de alta pureza | |
| NO20003698L (no) | Orale sammensetninger | |
| BR0116605A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono | |
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| BR9912813A (pt) | Derivados de fenil-prostaglandina e 5-tia-omega-substituìdos, processo para a produção dos mesmos e drogas contendo os mesmos como ingrediente ativo | |
| BRPI0007714B8 (pt) | processo para preparação de liofilizados da substância metanossulfanato de 2-metil-5-metilsulfonil-4-(1-pirrolil) benzoilguanidina que apresentam uma taxa de dissolução melhorada, e preparação farcêutica compreendendo os mesmos. | |
| BR9908015A (pt) | Composições que compreendem vìrus e métodos para concentração de preparações de vìrus | |
| BR0012488A (pt) | Composição farmacêutica, métodos para melhorar a taxa de absorção de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para melhorar o inìcio do benefìcio terapêutico de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para inibição de gastroirritação em um mamìfero, e para tratamento de mamìferos necessitando do tratamento proporcionado por um ou mais do que um agente farmaceuticamente ativo, e, processo para preparar uma composição farmacêutica | |
| BR9714634A (pt) | Carbamatos de benzimidazola-2 para o tratamento de infecções viróticas de câncer | |
| BRPI0011324B8 (pt) | agonistas de adrenoceptores beta 2, processo de preparação dos mesmos, seu uso e composição farmacêutica compreendendo os mesmos | |
| BR0111732A (pt) | Prodrogas de 2-deóxi-beta-l-nucleosìdeos | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| BR0012590A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central | |
| CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
| BR0015147A (pt) | Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos | |
| BR0208111A (pt) | Composto, utilização de um composto, processo de tratamento de distúrbios, processo para preparação de composto, composição farmacêutica que compreende o composto e processo de tratamento de obesidade | |
| BR9910329A (pt) | Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto | |
| CO5070569A1 (es) | Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen | |
| PE26898A1 (es) | Sales edulcorantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: A61K 9/19, A61K 31/165, A61K 31/155, A61K 31/40, A61P 9/00, A61P 43/00 Ipc: A61K 9/19 (2009.01), A61K 31/165 (2009.01), A61K 3 |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIDO O PEDIDO COM BASE NO ARTIGO 25 DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/09/2014, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/01/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 26/01/2020 |